Arcus Biosciences, Inc. (RCUS) is a publicly traded Healthcare sector company. As of October 26, 2026, RCUS trades at $17.34 with a market cap of $2.36B and a P/E ratio of -6.21. RCUS moved -4.21% today. Year to date, RCUS is -23.74%; over the trailing twelve months it is +2.60%. Its 52-week range spans $6.50 to $31.74. Analyst consensus is buy with an average price target of $40.25. Rallies surfaces RCUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Arcus reports 35-month median survival for casdatifan and prices $250 million share offering: Arcus priced an offering of 14,285,715 shares at $17.50 each, expecting $250 million in gross proceeds before fees and expenses; underwriters have a 30-day option to buy 2,142,857 additional shares. The company also reported median overall survival of 35 months for investigational casdatifan in a late-line kidney cancer study, supporting plans for a registrational trial with tivozanib.
| Metric | Value |
|---|---|
| Price | $17.34 |
| Market Cap | $2.36B |
| P/E Ratio | -6.21 |
| EPS | $-3.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $31.74 |
| 52-Week Low | $6.50 |
| Volume | 2.27M |
| Avg Volume | 0 |
| Revenue (TTM) | $117.00M |
| Net Income | $-460.00M |
| Gross Margin | 0.00% |
13 analysts cover RCUS: 0 strong buy, 9 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $40.25.